←
Ben Portney71 posts
Ben Portney avatar

Ben Portney

@BenPortney
◷ Joined October 2017
Ben Portney avatar
Ben Portney@BenPortney·16 Nov 2023

Understanding these market dynamics is crucial for making decisions in highly evolving therapeutic areas. We anticipate these modality battles to continue and are already seeing them play out in indications like SMA, hypercholesterolemia, ATTR Amyloidosis, and AAT deficiency

Ben Portney avatar
Ben Portney@BenPortney·16 Nov 2023

Biotech has seen a surge in the development of new modalities in recent years. At a16z bio+health, we spend a lot of time thinking about how new modalities fit into increasingly crowded indication landscapes.

Ben Portney avatar
Ben Portney@BenPortney·29 Mar 2023

Thrilled to be part of this years team and the opportunity to make an impact on such an important cause! Please consider donating: justgiving.com/fundraising/b…

The #TimmermanTraverse is back! @ldtimmerman is leading 20+ industry leaders up and over 7 mountain peaks to grow support for our programs & partnerships. Learn more: lifesciencecares.org/news/20… @LS_CaresSD @LS_CaresPhilly

Post attachment
Jorge Conde avatar
⟳ Ben Portney retweeted
Jorge Conde@JorgeCondeBio·2 Aug 2022

Cocktail therapies—combos of drugs that attack different parts of a virus—made HIV a manageable condition. Can we use precision cocktails to fight cancer? IDRx aims to punch back against cancer through intelligently designed combination therapies. 🥊🥊🥊 a16z.com/2022/08/02/investin…

Noubar Afeyan avatar
⟳ Ben Portney retweeted
Noubar Afeyan@NoubarAfeyan·14 Jun 2021

Today @FlagshipPioneer announced the close of a $3.4 billion capital pool that will enable us to accelerate the creation and growth of our next-generation bioplatform companies. flagshippioneering.com/press…